AstraZeneca trial data

Thank you for your email.  This auto-response is to inform you that your
email has been received and will be reviewed by our Customer Service Team.
We will respond to you as soon as possible. 
 
Please note that we may not respond if your query: 
 
• contains offensive language
• has already been answered in a previous reply to you
• is illegible
• is selling or promoting a product
• is for information only 
 
Medicines and Healthcare products Regulatory Agency
10 South Colonnade, 
Canary Wharf, 
London 
E14 4PU
gov.uk/mhra
Stay connected 
 
For information on how the Agency uses your personal data and your data
protection rights, please see our three centres’ Privacy Notices: MHRA,
CPRD and NIBSC. 
 
The UK has left the EU, and the transition period ends on 31 December
2020. Ourguidance and information can be accessed here.

________________________________________ From: vikki spit
<[FOI #863510 email]> Sent: Sunday, May 22, 2022
10:40:42 AM To: MHRA Customer Services Subject: Freedom of Information
request - AstraZeneca trial data Dear Medicines and Healthcare Products
Regulatory Agency, It is well known that the USA did not take up the AZ
vaccine as the Trisl data provided was incomplete and misleading. 1) can
you please share the trial data provided by AZ 2) is this the same data
rejected by the USA 3) does the trial data show any information about
VITT? Yours faithfully, vikki spit
------------------------------------------------------------------- Please
use this email address for all replies to this request:
[FOI #863510 email] Is [MHRA request email] the wrong
address for Freedom of Information requests to Medicines and Healthcare
Products Regulatory Agency? If so, please contact us using this form:
https://eur01.safelinks.protection.outlo...
Disclaimer: This message and any reply that you make will be published on
the internet. Our privacy and copyright policies:
https://eur01.safelinks.protection.outlo...
For more detailed guidance on safely disclosing information, read the
latest advice from the ICO:
https://eur01.safelinks.protection.outlo...
https://eur01.safelinks.protection.outlo...
Please note that in some cases publication of requests and responses will
be delayed. If you find this service useful as an FOI officer, please ask
your web manager to link to us from your organisation's FOI page.

show quoted sections

Our Ref: FOI 22/715

Dear Vikki Spit,

RE: REQUEST UNDER THE FREEDOM OF INFORMATION ACT 2000

Thank you for your enquiry which we received on 23rd May 2022.

I confirm that your request is now being handled under the Freedom of Information Act and you should receive a reply within 20 working days from our date of receipt.

If you need to contact us again about this request, please quote the reference number above.

Please be aware that we publish FOIs replies and these are redacted and are located on our website at the following link below.
https://www.gov.uk/government/collection...

Kind Regards,

MHRA Customer Experience Centre
Communications and engagement team
Medicines and Healthcare products Regulatory Agency
10 South Colonnade, Canary Wharf, London E14 4PU Telephone 020 3080 6000

show quoted sections

FOI 22/715

Dear Vikki Spit

Thank you for your email.

Regarding Q1, the clinical data for the AZ vaccine is available through the European Medicines Agency (EMA), link is provided below:

https://eur01.safelinks.protection.outlo...

Regarding Q2, as MHRA does not have access to the data package submitted by to the FDA, we cannot confirm whether the data is the same as the data submitted for UK authorisation.

Regarding Q3 (Vaccine-induced immune thrombotic thrombocytopenia (VITT)), the public assessment reports for the assessment of the AZ vaccine by the MHRA and the EMA are presented below:
https://eur01.safelinks.protection.outlo...

https://eur01.safelinks.protection.outlo...

https://eur01.safelinks.protection.outlo...

I can confirm that no reports, or other events suggestive of the very rare syndrome of thrombosis occurring with thrombocytopenia were reported in the clinical trials of the AstraZeneca COVID-19 vaccine. This risk was identified following receipt of Yellow Card reports of very unusual types of thrombosis occurring with thrombocytopenia in people who had received this vaccine, the MHRA undertook a thorough review into these reports

This scientific review concluded that the evidence of a link with COVID-19 Vaccine AstraZeneca was likely and on 7 April 2021, the MHRA issued a press release informing the public and healthcare professionals of the possible link between the AstraZeneca vaccine and rare blood clots with thrombocytopenia.

At the same time, the information leaflets for patients and healthcare professionals were updated to include information on the possible risk of extremely rare blood clots following this vaccine and advice on symptoms for vaccine recipients to look out for 4 or more days after vaccination.

These cases have also been analysed by the government's independent advisory body, the COVID-19 Vaccines Benefit Risk Expert Working Group, which includes lay representatives and advice from leading haematologists.

These events are extremely rare, with an incidence of 15.8 per million doses of vaccine given. The MHRA's advice remains that the benefits of the COVID-19 vaccine AstraZeneca outweigh the risks in the majority of people.

The MHRA continues to publish the latest breakdown of all cases of these extremely rare side effects on a weekly basis https://eur01.safelinks.protection.outlo...

The reason why some people develop these extremely rare blood clots with lowered platelets is not yet fully understood. The MHRA have requested that AstraZeneca conduct a series of studies to further investigate the syndrome of thrombosis with thrombocytopenia. These studies have been made a condition of the licence for this vaccine; therefore, AstraZeneca is obliged to conduct them to an agreed timescale and report the findings to the MHRA, and other global regulators for assessment. These studies are summarised in the Public Assessment Report for Vaxzevira (the COVID-19 Vaccine AstraZeneca) which can be found here.

Furthermore, a team of independent researchers and experts in epidemiology, immunology, neurology and haematology have convened a "Thrombosis and thrombocytopenia in COVID-19" Consortium. The Consortium aims to coordinate work in this area to enable further understanding of this syndrome. Specific research areas include investigation into background rates of these events in the general population, and the evaluation of the association between SARS-CoV-2 infection and thrombotic disorders, and COVID-19 vaccination and these events.

The MHRA will continue to carefully evaluate any emerging information on blood clots occurring with thrombocytopenia and will take regulatory action and communicate to the public and healthcare professionals as appropriate.

If you have a query about the information provided, please reply to this email.

If you disagree with how we have interpreted the Freedom of Information Act 2000 in answering your request, you can ask for an internal review. Please reply to this email, within two months of this reply, specifying that you would like an Internal Review to be carried out.

Please remember to quote the reference number above in any future communications.

If you were to remain dissatisfied with the outcome of the internal review, you would have the right to apply directly to the Information Commissioner for a decision. Please bear in mind that the Information Commissioner will not normally review our handling of your request unless you have first contacted us to conduct an internal review. The Information Commissioner can be contacted at:

Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF

Yours sincerely

MHRA Customer Experience Centre
Communications and engagement team
Medicines and Healthcare products Regulatory Agency
10 South Colonnade, Canary Wharf, London E14 4PU
Telephone 020 3080 6000

show quoted sections